Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06599762 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Study acronym: MYELO-CAN:TXA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 2 words
    • Study description expanded, about 3 words
    v5
  2. Phase: Not applicable to Phase 2
    • Start date changed from estimate of May 12, 2025 to Sep 10, 2025
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Apr 15, 2025 to May 12, 2025
    • Eligibility criteria expanded, about 3 words
    v3
  4. Start date: Nov 1, 2024 to Apr 15, 2025
    • Primary completion date: Nov 1, 2026 to Apr 1, 2027
    • Study completion date: Nov 1, 2027 to Apr 1, 2027
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Manitoba
108 trials monitored
See 7 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Acute Myeloid Leukemia (AML)
1,269 trials monitored
See 74 trials at risk
Myelodysplastic Syndromes (MDS)
711 trials monitored
See 42 trials at risk
and 1 more disease
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and/or severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.
Trial Details
NCT Number NCT06599762
Lead Sponsor University of Manitoba
Conditions
(from sponsor)		 Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
Related terms Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorders, Thrombocytopenia
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov